Bupivacaine

Generic Name: Bupivacaine

Brand Names: Exparel, Kenalog, Marbeta, Marcaine, Marcaine With Epinephrine, Marvona Suik, P-Care M, P-Care MG, P-care, Posimir, Readysharp Anesthetics Plus Ketorolac, Readysharp-A, Readysharp-p40, Readysharp-p80, Sensorcaine, Sensorcaine With Epinephrine, Vivacaine, Xaracoll, Exparel liposomal

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₂₈N_₂O

CAS Number: 38396-39-3

Unique Ingredient Identifier: Y8335394RO

Background: Bupivacaine is a widely used local anesthetic agent.

Indication: As an implant, bupivacaine is indicated in adults for placement into the surgical site to produce postsurgical analgesia for up to 24 hours following open inguinal hernia repair.

Bupivacaine, in liposome suspension, is indicated in patients aged 6 years and older for single-dose infiltration to produce postsurgical local analgesia. In adults, it is also indicated as an interscalene brachial plexus nerve block to produce postsurgical regional analgesia.

Bupivacaine, in combination with meloxicam, is indicated for postsurgical analgesia in adult patients for up to 72 hours following foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures.

Bupivacaine, alone or in combination with epinephrine, is indicated in adults for the production of local or regional anesthesia or analgesia for surgery, dental and oral surgery procedures, diagnostic and therapeutic procedures, and for obstetrical procedures. Specific concentrations and presentations are recommended for each type of block indicated to produce local or regional anesthesia or analgesia. Finally, its use is not indicated in all blocks given clinically significant risks associated with use.

Associated Conditions: Acute Gouty Arthritis, Adrenocortical Insufficiency, Alopecia Areata (AA), Ankylosing Spondylitis (AS), Berylliosis, Bullous dermatitis herpetiformis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Dermatomyositis (DM), Discoid Lupus Erythematosus (DLE), Edema of the cerebrum, Epicondylitis, Hemolytic Anemia, Hypercalcemia caused by Cancer, Keloids Scars, Leukemias, Mycosis Fungoides (MF), Necrobiosis lipoidica diabeticorum, Ocular Inflammation, Ophthalmia, Sympathetic, Osteoarthritis (OA), Pain, Labor, Polymyositis, Postoperative pain, Psoriatic Arthritis, Psoriatic plaque, Pure Red Cell Aplasia, Regional Enteritis, Rheumatoid Arthritis, Secondary thrombocytopenia, Stevens-Johnson Syndrome, Synovitis, Systemic Lupus Erythematosus, Temporal Arteritis, Trichinosis, Tuberculous Meningitis, Ulcerative Colitis, Uveitis, Acute Bursitis, Acute Idiopathic Nephrotic Syndrome, Acute Lupus Erythematosus, Acute Multiple sclerosis, Acute Rheumatic heart disease, unspecified, Acute nonspecific tenosynovitis, Cystic tumors of aponeurosis, Cystic tumors of tendon, Disseminated Pulmonary Tuberculosis (TB), Exfoliative erythroderma, Inflammatory lesions of granuloma annulare, Inflammatory lesions of lichen planus, Inflammatory lesions of lichen simplex, Non-suppurative Thyroiditis, Permphigus, Severe Allergic Reactions

Associated Therapies: General Anesthesia, Local Anaesthesia therapy, Regional nerve block therapy

Clinical Trials

Effect of Adding Different Concentrations of Dexmedetomidine to Bupivacaine in Caudal Block for Pediatrics

Phase 1

Not yet recruiting

Conditions: Caudal Block for Postoperative Analgesia

Interventions: Drug: Dexmedetomidine
Drug: Bupivacain

First Posted Date: 2024-10-31

Last Posted Date: 2024-11-13

Lead Sponsor: Assiut University

Target Recruit Count: 50

Registration Number: NCT06668220

Dexmedetomidine as an Intrathecal Adjuvant to Hyperbaric Bupivacaine for Postoperative Analgesia in Patients Undergoing Arthroscopic Anterior Cruciate Ligament Reconstruction Surgeries

Not Applicable

Completed

Conditions: Dexmedetomidine
Intrathecal
Adjuvant
Hyperbaric Bupivacaine
Analgesia
Arthroscopic Anterior Cruciate Ligament Reconstruction

Interventions: Drug: Hyperbaric bupivacaine
Drug: Dexmedetomidine and Hyperbaric bupivacaine

First Posted Date: 2024-10-31

Last Posted Date: 2024-10-31

Lead Sponsor: Tanta University

Target Recruit Count: 64

Registration Number: NCT06667024

Locations: 🇪🇬
Tanta University, Tanta, El-Gharbia, Egypt

Dexmedetomidine and Bupivacaine Intra-articular for Postoperative Analgesia After Knee Arthroscopic Surgery

Phase 3

Recruiting

Conditions: Post Operative Analgesia

Interventions: Drug: Normal Saline (Placebo)
Drug: Bupivacaine 0.25%
Drug: Dexmedetomidine

First Posted Date: 2024-10-30

Last Posted Date: 2025-04-22

Lead Sponsor: Al-Azhar University

Target Recruit Count: 75

Registration Number: NCT06665438

Locations: 🇪🇬
Al-Azhar University, Assiut, Egypt

Role of Dexmedetomidine as Synergistic Agent

Phase 2

Not yet recruiting

Conditions: Dexmedetomidine
Hyperbaric Bupivacaine
Subarachnoid Anesthesia

Interventions: Drug: hyperbaric bupivacaine and dexmedetomidine
Drug: Hyperbaric bupivacaine

First Posted Date: 2024-10-28

Last Posted Date: 2024-10-28

Lead Sponsor: Lady Reading Hospital, Pakistan

Target Recruit Count: 166

Registration Number: NCT06662175

Locations: 🇵🇰
Lady Reading Hospital Mti Peshawar Kp Pakistan, Peshawar, KPK, Pakistan

EOIB for Laparoscopic Cholecystectomy

Not Applicable

Recruiting

Conditions: Cholecystitis
Cholecystitis, Acute
Cholecystitis, Chronic
Cholecystitis; Gallstone

Interventions: Device: ultrasound guided external oblique intercostal plane block
Drug: Bupivacaine injection
Drug: paracetamol, tramadol, and ondansetron